Home > Healthcare > Medical Devices > Diagnostic Devices > IVD in Cardiology and Neurology Market

IVD in Cardiology and Neurology Market Trends

Report ID: GMI8846
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

IVD in Cardiology and Neurology Market Trends

Advances in in-vitro diagnostics (estimated to reach USD 141 billion by 2032), technologies, including molecular diagnostics, next-generation sequencing, imaging modalities, and biomarker discovery, have led to the development of more sensitive, specific, and efficient diagnostic tests for cardiovascular and neurological conditions. These technological advancements enable healthcare providers to diagnose diseases more accurately, assess disease severity, predict treatment response, and monitor disease progression with greater precision.

There is a growing emphasis on research and development efforts aimed at identifying novel biomarkers, imaging techniques, and diagnostic algorithms for cardiovascular and neurological disorders.
The focus on innovation drives the development of new diagnostic tests that improve sensitivity, specificity, and predictive value, ultimately leading to better patient outcomes through early detection, personalized treatment approaches, and effective disease management.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

IVD in cardiology and neurology industry size was USD 15.6 billion in 2023 and is estimated to exceed USD 24 billion by 2032, due to increasing incidence and prevalence of cardiovascular diseases (CVDs) and neurological disorders like Alzheimer's disease, Parkinson's disease, and stroke.

The reagents, kits, & consumables product type segment is estimated to record USD 12 billion by the end of 2032, owing to higher adoption in diagnostic testing for cardiovascular and neurological disorders.

North America held 40.8% of the IVD in cardiology and neurology industry share in 2023, and will witness significant growth till 2032, due to presence of well-established healthcare infrastructure, advanced diagnostic technologies, and a strong emphasis on R&D in the field of medicine.

Abbott Laboratories, Becton, Dickinson, and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.